Fate Therapeutics, Inc. (FATE) Financials

FATE Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 260.1 million 106.7 million
March 31, 2026 284.9 million 105.2 million
Dec. 31, 2025 318.9 million 111.8 million
Sept. 30, 2025 343.7 million 109.6 million

FATE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -23.5 million 3.5 million
March 31, 2026 -31.1 million 3.9 million
Dec. 31, 2025 -24.5 million 5.5 million
Sept. 30, 2025 -26.6 million 4.9 million

FATE Net Income

No data available :(

FATE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 153.8 million - -
March 31, 2026 174.8 million - 76.8 million
Dec. 31, 2025 203.7 million - 77.8 million
Sept. 30, 2025 215.4 million - 79.2 million

FATE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 120.4 million
March 31, 2026 120.0 million
Dec. 31, 2025 118.8 million
Sept. 30, 2025 119.0 million

FATE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 80000 24.4 million 8.8 million -
March 31, 2026 239000 21.8 million 9.6 million -
Dec. 31, 2025 1.2 million 25.4 million 10.7 million -
Sept. 30, 2025 2.2 million 25.8 million 10.6 million -

FATE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 2.1 million -
March 31, 2026 1.3 million 2.9 million
Dec. 31, 2025 1.4 million 3.1 million
Sept. 30, 2025 1.7 million 25.8 million

FATE Revenue by Segment
Graph available only for paid members. Upgrade to see it.

FATE

Price: $1.79

52 week price:
0.95
3.23

Earnings Per Share: -1.09 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.6 million

Ebitda: -10.1 million

Market Capitalization: 278.0 million

Links: